The secondary objectives were to: i) assess progression free survival (PFS) at 16 weeks; ii) determine overall survival (OS); iii) describe the toxicities of bevacizumab in liver disease; iv) evaluate the pharmacokinetics (PK) of bevacizumab in liver disease; and v) measure VEGF before and after TACE with and without bevacizumab. Here, VEGFA is linked to liver disorder.